In patients with stage III non–small-cell lung cancer (NSCLC) whose disease did not progress after 2 or more cycles of platinum-based chemoradiotherapy, use of durvalumab as consolidation therapy significantly improved progression-free survival. Read More ›

According to the results of a recent phase 2 clinical trial, treatment with a regimen of dabrafenib, an oral BRAF inhibitor, plus trametinib, an MEK inhibitor, is effective and tolerable in previously untreated patients with BRAF V600E‒mutated metastatic non–small-cell lung cancer (NSCLC). Read More ›

Rovalpituzumab tesirine, an investigational antibody-drug conjugate that targets delta-like protein 3, shows encouraging single-agent efficacy with a manageable safety profile in the treatment of patients with recurrent small-cell lung cancer, according to recently published results. Read More ›

The role of nurse navigators has grown exponentially in recent years, and is now regarded as an integral element of oncology treatment and patient care. The Academy of Oncology Nurse & Patient Navigators (AONN+) defines patient navigation as the “process whereby a patient is given individualized support across the continuum of care, beginning with community outreach to raise awareness and perform cancer screening, through the diagnosis and treatment process, and on to short- and long-term survivorship or end of life.” At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer. Read More ›